VPA10988/108/001

Virbamec Super Solution For Injection

Variation	Summary	Date
Vet - B27 a)	VNRA - Vet - B27 a) - a) Tightening of in-process limits - B27 a) Changes to the quality part of the dossier: Change to in-process tests or limits applied during the manufacture of the finished product: — tightening of in-process limits	23/04/24
Vet - F.I.b.1 b)	VRA-S - Vet - F.I.b.1 b) - b) Change outside the approved specifications limits range for the active substance - F.I.b.1 b) Quality Changes - Active Substance - Control of active substance -Change in the specification parameters and/or limits of an active substance, starting material/intermediate/reagent used in the manufacturing process of the active substance - Change outside the approved specifications limits range for the active substance	12/04/24
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	12/04/24
Vet - B3 f)	VNRA - Vet - B3 f) - f) Deletion of one of the authorised bulk or final containers (including packaging of an active substance) or immediate packaging of the finished product that does not lead to the complete deletion of a strength or pharmaceutical form - B3 f) Changes to the quality part of the dossier: Deletion of one of the authorised bulk or final containers (including packaging of an active substance) or immediate packaging of the finished product that does not lead to the complete deletion of a strength or pharmaceutical form	11/04/24
Vet - F.II.e.4 b)	VRA-R - Vet - F.II.e.4 b) - b) Sterile medicinal products - F.II.e.4 b) Quality Changes - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	19/03/24
Vet - F.II.e.4 b)	VRA-R - Vet - F.II.e.4 b) - b) Sterile medicinal products - F.II.e.4 b) Quality Changes - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	19/03/24
Vet - F.II.e.4 b)	VRA-R - Vet - F.II.e.4 b) - b) Sterile medicinal products - F.II.e.4 b) Quality Changes - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	19/03/24
Vet - F.II.e.7 z)	VRA-R - Vet - F.II.e.7 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.7 z) Quality Changes - Container closure system - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other	19/03/24

	changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	11/05/23
Vet - F.I.a.1 a)	VRA-S - Vet - F.I.a.1 a) - a) Introduction of a manufacturer of the active substance supported by an ASMF - F.I.a.1 a) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	22/12/22